JPRN-UMIN000014560已完成1 期
Phase 1/2 study of triple combination chemotherapy with Carboplatin, nab-Paclitaxel, and Bevacizumab for chemotherapy-naïve stageIIIB/IV non- squamous non-small-cell lung cancer (TORG1424/OLCSG1402) - CARboplatin, Nab-paclitaxel and AVAstin for non-small cell Lung cancer(CARNAVAL) (TORG1424/OLCSG1402)
Thoracic Oncology Research Group0 个研究点目标入组 55 人开始时间: 2014年7月30日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Symptomatic brain metastasis. 2) Current history of hemoptysis. 3) History of hypersensitivity for therapeutic agent or albumin products 4) With grade2 or more neuropathy 5) Uncontrolled ascites, pleural effusion or cardiac effusion. 6) Within 2 weeks after palliative radiotherapy 7) Within 4 weeks after operation 8) Active double malignancies 9) Fever over 38C 10) serious medical complications 11) Receiving anticoagulant drug (325mg and less aspirin is possible) 12) Pregnancy, breastfeeding or suspected of being pregnant 13) HBs positive patient 14) Others judged by attending physician
研究者
相似试验
已完成
2 期
Phase II study of combination chemotherapy in treating pediatric patients with newly diagnosed intracranial germinomaJPRN-UMIN000002397Japanese Pediatric Brain Tumor Consortium50
已完成
2 期
A Phase II study of combination chemotherapy including Bortezomib in pediatric patients with relapsed acute lymphoblastic leukemia (Investigator-initiated clinical trial)A high-risk group of pediatric patients with first relapse of ALLor refractory ALL (patients who develop 2nd or subsequent relapse, relapse after hematopoietic cell transplantation or fail to achieve remission induction with one or more therapies).JPRN-UMIN000023815Department of Pediatric Oncology, National Cancer Center Hospital22
进行中（未招募）
1 期
Phase III study of chemotherapy in combination with ATRA with or without gemtuzumab ozogamicin in patients with acute myeloid leukemia and NPM1 gene mutatioadult patients with AML and NPM1 mutationEUCTR2009-011889-28-ATniversity of Ulm588
进行中（未招募）
1 期
Phase III study of chemotherapy in combination with ATRA with or without gemtuzumab ozogamicin in patients with acute myeloid leukemia and NPM1 gene mutatioEUCTR2009-011889-28-DEniversity of Ulm588
未知
2 期
A phase II study of combination chemotherapy of oral tegafur/uracil, leucovorin and bevacizumab for patients not appropriate for intensive therapy with unresectable or recurrent colorectal cancerunresectable metastatic/recurrent colorectal cancerJPRN-UMIN000024330Dept of Surgical Oncology Osaka City University Graduate School of Medicine35